Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2016

12.05.2016 | Original Research

Efficacy of Omega Fatty Acid Supplementation on mRNA Expression Level of Tumor Necrosis Factor Alpha in Patients with Gastric Adenocarcinoma

verfasst von: Asghar Hosseinzadeh, Seyed Mojtaba Mohaddes Ardebili

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Tumor necrosis factor alpha (TNF-α), a multifunctional cytokine, is involved in apoptosis, cell proliferation, cell survival, and inflammation. It plays a dual role in cancer development and progression. It has been revealed that polyunsaturated fatty acids (PUFAs) modulate the production and activity of TNF family cytokines. The objective of the present study was to evaluate the effect of PUFAs on messenger RNA expression levels of TNF-α in patients with gastric adenocarcinoma.

Methods

Thirty-four chemotherapy-naive patients diagnosed with gastric adenocarcinoma were randomly divided into two groups. The first group (17 individuals) received cisplatin without supplements and the second group (17 individuals) received cisplatin plus orally administered PUFA supplements for 3 weeks, based on treatment strategies. The gastric biopsy samples were obtained from all participants before and after treatment, and TNF-α mRNA expression levels were evaluated by quantitative real-time PCR procedure.

Results

Our findings revealed that TNF-α mRNA expression is downregulated in group II, after receiving cisplatin and omega fatty acid supplement for 3 weeks. However, this difference is not statistically significant (p > 0.05). TNF-α mRNA expression did not show significant alteration in group I, after receiving cisplatin alone.

Conclusions

Taken together, we concluded that omega fatty acids reduce TNF-α expression at the mRNA level in patients with gastric adenocarcinoma. These data suggest that TNF-α may act as a potential target for the therapy of human gastric adenocarcinoma.
Literatur
1.
Zurück zum Zitat de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013;42(2):219–40.CrossRefPubMed de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013;42(2):219–40.CrossRefPubMed
2.
Zurück zum Zitat Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–13.CrossRefPubMedPubMedCentral Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–13.CrossRefPubMedPubMedCentral
3.
4.
Zurück zum Zitat Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad M, Sepehrizadeh Z, Roshandel G, Ebrahimifard F, Setayesh N. Identification of novel genes involved in gastric carcinogenesis by suppression subtractive hybridization. Hum Exp Toxicol. 2015;34(1):3–11.CrossRefPubMed Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad M, Sepehrizadeh Z, Roshandel G, Ebrahimifard F, Setayesh N. Identification of novel genes involved in gastric carcinogenesis by suppression subtractive hybridization. Hum Exp Toxicol. 2015;34(1):3–11.CrossRefPubMed
5.
Zurück zum Zitat Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143–6.PubMed Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143–6.PubMed
6.
Zurück zum Zitat McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11(11):664–74.CrossRefPubMed McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11(11):664–74.CrossRefPubMed
9.
Zurück zum Zitat Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.CrossRefPubMedPubMedCentral Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Yu M, Zhou X, Niu L, Lin G, Huang J, Zhou W, et al. Targeting transmembrane TNF-α suppresses breast cancer growth. Cancer Res. 2013;73(13):4061–74.CrossRefPubMed Yu M, Zhou X, Niu L, Lin G, Huang J, Zhou W, et al. Targeting transmembrane TNF-α suppresses breast cancer growth. Cancer Res. 2013;73(13):4061–74.CrossRefPubMed
11.
Zurück zum Zitat Robache-Gallea S, Morand V, Bruneau JM, Schoot B, Tagat E, Réalo E, et al. In vitro processing of human tumor necrosis factor-alpha. J Biol Chem. 1995;270(40):23688–92.CrossRefPubMed Robache-Gallea S, Morand V, Bruneau JM, Schoot B, Tagat E, Réalo E, et al. In vitro processing of human tumor necrosis factor-alpha. J Biol Chem. 1995;270(40):23688–92.CrossRefPubMed
12.
Zurück zum Zitat Kirkegaard T, Pedersen G, Saermark T, Brynskov J. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol. 2004;135(1):146–53.CrossRefPubMedPubMedCentral Kirkegaard T, Pedersen G, Saermark T, Brynskov J. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol. 2004;135(1):146–53.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early diagnosis and prognosis (review). Oncol Lett. 2015;9(4):1502–8.PubMedPubMedCentral Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early diagnosis and prognosis (review). Oncol Lett. 2015;9(4):1502–8.PubMedPubMedCentral
15.
Zurück zum Zitat Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett. 1995;95(1-2):207–12.CrossRefPubMed Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett. 1995;95(1-2):207–12.CrossRefPubMed
16.
Zurück zum Zitat Macrì A, Versaci A, Loddo S, Scuderi G, Travagliante M, Trimarchi G, et al. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers. 2006;11(2):184–93.CrossRefPubMed Macrì A, Versaci A, Loddo S, Scuderi G, Travagliante M, Trimarchi G, et al. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers. 2006;11(2):184–93.CrossRefPubMed
17.
Zurück zum Zitat Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology. 2001;48(40):1199–201.PubMed Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology. 2001;48(40):1199–201.PubMed
18.
Zurück zum Zitat Izutani R, Katoh M, Asano S, Ohyanagi H, Hirose K. Enhanced expression of manganese superoxide dismutase mRNA and increased TNFalpha mRNA expression bygastric mucosa in gastric cancer. World J Surg. 1996;20(2):228–33.CrossRefPubMed Izutani R, Katoh M, Asano S, Ohyanagi H, Hirose K. Enhanced expression of manganese superoxide dismutase mRNA and increased TNFalpha mRNA expression bygastric mucosa in gastric cancer. World J Surg. 1996;20(2):228–33.CrossRefPubMed
19.
Zurück zum Zitat Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6(6):461–7.CrossRefPubMed Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6(6):461–7.CrossRefPubMed
20.
Zurück zum Zitat Kang JX, Weylandt KH. Modulation of inflammatory cytokines by omega-3 fatty acids. Subcell Biochem. 2008;49:133–43.CrossRefPubMed Kang JX, Weylandt KH. Modulation of inflammatory cytokines by omega-3 fatty acids. Subcell Biochem. 2008;49:133–43.CrossRefPubMed
21.
Zurück zum Zitat Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4(9):565–73.CrossRefPubMed Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4(9):565–73.CrossRefPubMed
22.
Zurück zum Zitat Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14(3):171–9.CrossRefPubMed Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14(3):171–9.CrossRefPubMed
23.
Zurück zum Zitat Nabors LB, Suswam E, Huang Y, Yang X, Johnson MJ, King PH. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res. 2003;63(14):4181–7.PubMed Nabors LB, Suswam E, Huang Y, Yang X, Johnson MJ, King PH. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res. 2003;63(14):4181–7.PubMed
24.
Zurück zum Zitat Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461–6.CrossRefPubMed Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461–6.CrossRefPubMed
25.
Zurück zum Zitat Prévost-Blondel A, Roth E, Rosenthal FM, Pircher H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol. 2000;164(7):3645–51.CrossRefPubMed Prévost-Blondel A, Roth E, Rosenthal FM, Pircher H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol. 2000;164(7):3645–51.CrossRefPubMed
26.
Zurück zum Zitat Abdollahi H, Shams S, Zahedi MJ, DarvishMoghadam S, Hayatbakhsh MM, Jafarzadeh A. IL-10, TNF-α and IFN-γ levels in serum and stomach mucosa of Helicobacter pylori-infected patients. Iran J Allergy Asthma Immunol. 2011;10(4):267–71.PubMed Abdollahi H, Shams S, Zahedi MJ, DarvishMoghadam S, Hayatbakhsh MM, Jafarzadeh A. IL-10, TNF-α and IFN-γ levels in serum and stomach mucosa of Helicobacter pylori-infected patients. Iran J Allergy Asthma Immunol. 2011;10(4):267–71.PubMed
27.
Zurück zum Zitat Guiraldes E, Duarte I, Peña A, Godoy A, Espinosa MN, Bravo R, et al. Proinflammatory cytokine expression in gastric tissue from children with Helicobacter pylori-associated gastritis. J Pediatr Gastroenterol Nutr. 2001;33(2):127–32.CrossRefPubMed Guiraldes E, Duarte I, Peña A, Godoy A, Espinosa MN, Bravo R, et al. Proinflammatory cytokine expression in gastric tissue from children with Helicobacter pylori-associated gastritis. J Pediatr Gastroenterol Nutr. 2001;33(2):127–32.CrossRefPubMed
28.
Zurück zum Zitat Senthilkumar C, Niranjali S, Jayanthi V, Ramesh T, Devaraj H. Molecular and histological evaluation of tumor necrosis factor-alpha expression in Helicobacter pylori-mediatedgastric carcinogenesis. J Cancer Res Clin Oncol. 2011;137(4):577–83.CrossRefPubMed Senthilkumar C, Niranjali S, Jayanthi V, Ramesh T, Devaraj H. Molecular and histological evaluation of tumor necrosis factor-alpha expression in Helicobacter pylori-mediatedgastric carcinogenesis. J Cancer Res Clin Oncol. 2011;137(4):577–83.CrossRefPubMed
29.
Zurück zum Zitat Sun J, Aoki K, Zheng JX, Su BZ, Ouyang XH, Misumi J. Effect of NaCl and Helicobacter pylori vacuolating cytotoxin on cytokine expression and viability. World J Gastroenterol. 2006;12(14):2174–80.CrossRefPubMedPubMedCentral Sun J, Aoki K, Zheng JX, Su BZ, Ouyang XH, Misumi J. Effect of NaCl and Helicobacter pylori vacuolating cytotoxin on cytokine expression and viability. World J Gastroenterol. 2006;12(14):2174–80.CrossRefPubMedPubMedCentral
Metadaten
Titel
Efficacy of Omega Fatty Acid Supplementation on mRNA Expression Level of Tumor Necrosis Factor Alpha in Patients with Gastric Adenocarcinoma
verfasst von
Asghar Hosseinzadeh
Seyed Mojtaba Mohaddes Ardebili
Publikationsdatum
12.05.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2016
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9826-4

Weitere Artikel der Ausgabe 3/2016

Journal of Gastrointestinal Cancer 3/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.